Introduction
Non-invasive Prenatal Screening Version 2.0 (NIPSv2.0) is a newly ungraded product of NIPSv1.0, which can test 131 chromosomal diseases with clinical significance.
Advantages
- COMPREHENSIVE TESTING131 diseases are detected at once.
- ACCURACYan innovative NIPS-SCCD analytical workflow provides high accuracy.
- GOOD SAFETYonly requires the peripheral blood of pregnant women without the risks of abortion.
- AUTHORITATIVE RECOMMENDATIONInternational Society for Prenatal Diagnosis (ISPD) recommends NIPSv2.0 for chromosomal abnormalities
Applicable
- NIPSv2.0 is appropriate for pregnant women with fully informed consent, particularly those with a singleton or twin pregnancy at 12–22 weeks of gestation.
- Pregnant women who are at moderate risk of common chromosome aneuploidy through Down's serological screening and ultrasonic imaging examination;
- Pregnant women with contraindications to invasive prenatal diagnosis (such as threatened abortion, fever, bleeding tendency, and unhealed infection, etc.);
- Pregnant women who missed the optimal time for serological screening or prenatal diagnosis.